United States Biodefense-Related Rapid Pathogen Identification and Treatments Markets Outlook Report: Data from 2019-2020, estimates for 2021 and CAGR projections to 2026
12 nov. 2021 05h13 HE
|
Research and Markets
Dublin, Nov. 12, 2021 (GLOBE NEWSWIRE) -- The "The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments 2021-2026" report has been added to ResearchAndMarkets.com's...
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
17 juin 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
VaxInnate Enhances R&D Program and Strengthens Senior Management Team to Drive Pipeline Development of Current and Potential Targets
13 mai 2015 08h00 HE
|
Scienta Communications
Cranbury, NJ, May 13, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced two strategic
promotions and two additions to...
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
07 avr. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines
17 févr. 2015 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced that it has
executed a contract modification...
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
08 déc. 2014 08h00 HE
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
26 août 2013 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread
20 août 2013 11h21 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...